MatthewCFosterMD
Oncology • Chapel Hill, NCHematologic Oncology
Assistant Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine
Dr. Foster is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
101 Manning Dr
Chapel Hill, NC 27514Phone+1 984-974-0000Fax+1 919-843-6949- Is this information wrong?
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2006 - 2009- University of North Carolina HospitalsResidency, Internal Medicine, 2002 - 2005
University of North Carolina at Chapel Hill School of MedicineClass of 2002
Certifications & Licensure
NC State Medical License 2005 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias Start of enrollment: 2010 Sep 01
- Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction Start of enrollment: 2012 Jun 28
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsA study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.Cai, S., Huang, Y., Lance, J., Mao, H., Dunbar, A., McNulty, S., Druley, T., Li, Y., Baer, M., Stock, W., Kovacsovics, T., Blum, W., Schiller, G., Olin, R., Foran, J.,...> ;Blood Advances. 2024 Jan 23
- Comprehensive genomic profiling reveals molecular subsets of-mutated myeloid neoplasms.Steven M Johnson, James Haberberger, Jonathan Galeotti, Lori Ramkissoon, Catherine C Coombs, Daniel R Richardson, Matthew C Foster, Daniel Duncan, Nathan D Montgomery,...> ;Leukemia & Lymphoma. 2024 Feb 1
- 1 citationsA reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease.Steven M Johnson, James Haberberger, Jonathan Galeotti, Lori Ramkissoon, Catherine C Coombs, Daniel R Richardson, Matthew C Foster, Daniel Duncan, Joshua F Zeidner, Na...> ;Blood Cancer Journal. 2023 Jun 26
- Join now to see all
Abstracts/Posters
- Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AMLMatthew C Foster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Oral Adherence in Adults with Acute Myeloid Leukemia: Results of a Mixed Methods StudyMatthew C Foster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...Matthew C Foster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Trials and Tribulations of Corrected QT Interval Monitoring in Oncology: Rationale for a Practice-Changing Standardized ApproachJuly 16th, 2019
Duke Researchers Discover How Leukemia Spreads to the BrainAugust 8th, 2018
Professional Memberships
- Member
Hospital Affiliations
University of North Carolina HospitalsChapel Hill, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
